市场概况

The market for therapeutics to treat Crohn’s disease is projected to grow at a CAGR of 7.6% 从 2023 到 2029, reaching USD 23.63 十亿 2029, compared to USD 13.86 十亿 2022. Crohn’s disease, an inflammatory bowel disease, causes digestive tract inflammation and symptoms like abdominal pain, severe diarrhea, and weight loss. The market is dominated by Crohn’s disease in the inflammatory bowel disease treatment sector. The US has the highest prevalence of Crohn’s disease, followed by the UK and China. The rising prevalence drives the market’s growth. Over 100 assets are in development for Crohn’s disease, with most in Phase II. Anti-interleukin and integrin antibodies are the primary drugs in the pipeline. The US leads in global clinical trials. Biologics like anti-TNFs are widely used, but new therapies with better mechanisms of action and convenience are needed. Microbiome-based therapeutics show promise. Major companies invest in research, 收购, and collaborations. Multiple therapies have been launched, including Humira, Remicade, and Stelara. Five major companies have approved drugs for Crohn’s disease.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global Crohn’s disease therapeutics market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, including drug class, gender type, 年龄阶层, disease type, 和地理.
Drug class: 5-aminosalicylates, TNF-alpha inhibitors, 其他的
Gender: 男人, 女性
年龄阶层: 49 yrs. & 以下, 50 yrs. & 多于
Disease type: large intestinal type, small intestinal type, small/large intestinal type

按地理位置细分
北美 – 美国
Europe – Germany, 法国, 英国, 意大利, 西班牙
亚太地区 – 中国, 日本

TNF-Alpha inhibitors hold a significant share in the global Crohn’s disease therapeutics market, but other drug classes are expected to grow rapidly. Skyrizi’s approval will drive the market. New mechanisms of action are being researched to address non-response issues. Launch of new drugs for moderate-to-severe patients will contribute to market growth. Anti-integrin and interleukin inhibitors gain popularity. Women have a substantial presence. The small intestinal type grows fastest. Individuals aged 49 and below dominate. The US dominates, but the UK will grow rapidly. Biosimilars impact China and Japan.

竞争格局

The Crohn’s disease treatment market is dominated by generic medication providers and selective pharmaceutical and biotechnology companies. Key companies in this market include AbbVie Inc., 阿斯利康公司, Biogen Inc., 勃林格殷格翰国际有限公司, 百时美施贵宝公司, Celltrion, 公司, 约翰逊 & 约翰逊 (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA, 除其他外.

最新行业发展

AbbVie achieved a significant milestone in June 2022 with the FDA approval of SKYRIZI (risankizumab-rzaa), the first and only IL-23 inhibitor for moderately to severely active Crohn’s disease (CD). The approval was based on positive results from the ADVANCE and MOTIVATE studies, which evaluated risankizumab’s efficacy and safety in comparison to placebo.

In May 2022, AbbVie announced positive topline results from the Phase 3 U-ENDURE maintenance study, showing that upadacitinib demonstrated superior efficacy compared to placebo in achieving endoscopic response and clinical remission in patients with moderate to severe Crohn’s disease.

Ossium Health received FDA acceptance of its IND application for OSSM-001 in March 2022. OSSM-001, a mesenchymal stem cell product, aims to treat refractory perianal fistulas in Crohn’s disease patients. Ossium is now preparing for a Phase 1 clinical trial to evaluate the safety and efficacy of OSSM-001, expected to begin by the end of 2022.

报告范围

To analyze and forecast the market size of the global Crohn’s disease therapeutics market.
To classify and forecast the global Crohn’s disease therapeutics market based on drug class, gender, 年龄阶层, disease type, 地理.
To identify drivers and challenges for the global Crohn’s disease therapeutics market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global Crohn’s disease therapeutics market.
To identify and analyze the profile of leading players operating in the global Crohn’s disease therapeutics market.

为什么选择这份报告

Gain a reliable outlook of the global Crohn’s disease therapeutics market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.